• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

四十年造血干细胞移植:巴塞尔经验回顾。

Forty years of haematopoietic stem cell transplantation: a review of the Basel experience.

机构信息

Behandlungszentrum Stammzelltransplantation, Basel University Hospital, SWITZERLAND;

出版信息

Swiss Med Wkly. 2014 Feb 24;144:w13928. doi: 10.4414/smw.2014.13928.

DOI:10.4414/smw.2014.13928
PMID:24567259
Abstract

The purpose of this study was to examine changes in haematopoietic stem cell transplant (HSCT) characteristics and outcome in our combined paediatric and adult programme over the past four decades, since its implementation in 1973. The total number of transplant procedures rose from 109 in the first decade (1973-82) to 939 in the last decade (2003-12). Transplant characteristics changed significantly over time: patient age increased, peripheral blood largely replaced bone marrow as stem cell source, unrelated donors became an alternative to matched siblings, and patients are increasingly transplanted in more advanced disease stages. Advances such as improved supportive care and histocompatibility typing resulted in a steady decrease of transplant-related mortality after allogeneic HSCT (43% in the first decade, 22% in the last decade). Despite this, unadjusted survival rates were stable in the last three decades for allogeneic HSCT (approximately 50% 5-year survival) and in the last two decades for autologous HSCT (approximately 60% 5-year survival). After adjustment for covariates such as donor type, age and stage, the relative risk of treatment failure continuously dropped (for allogeneic HSCT: first decade 1.0, second decade 0.58, third decade 0.51, last decade 0.41). Collectively, these data suggest that improvements in peri- and post-transplant care have allowed considerable extension of transplant indications without having a negative impact on outcome.

摘要

本研究旨在探讨过去四十年间,自 1973 年开展造血干细胞移植(HSCT)以来,我们的儿科和成人联合项目中 HSCT 特征和结果的变化。移植例数从第一个十年(1973-82 年)的 109 例增加到最后一个十年(2003-12 年)的 939 例。移植特征随时间发生了显著变化:患者年龄增加,外周血逐渐取代骨髓作为干细胞来源,非亲缘供者成为匹配同胞供者的替代方案,且患者越来越多地在疾病更晚期接受移植。由于支持性治疗和组织相容性配型的进步,异基因 HSCT 后的移植相关死亡率稳步下降(第一个十年为 43%,最后一个十年为 22%)。尽管如此,在过去三个十年中,异基因 HSCT 的未调整生存率保持稳定(约 50%的 5 年生存率),在过去两个十年中,自体 HSCT 的生存率保持稳定(约 60%的 5 年生存率)。在调整了供者类型、年龄和疾病分期等协变量后,治疗失败的相对风险持续下降(对于异基因 HSCT:第一个十年为 1.0,第二个十年为 0.58,第三个十年为 0.51,最后一个十年为 0.41)。总的来说,这些数据表明,移植前后护理的改进使得移植适应证得以显著扩展,而不会对结果产生负面影响。

相似文献

1
Forty years of haematopoietic stem cell transplantation: a review of the Basel experience.四十年造血干细胞移植:巴塞尔经验回顾。
Swiss Med Wkly. 2014 Feb 24;144:w13928. doi: 10.4414/smw.2014.13928.
2
[Efficacy of donor lymphocyte infusion in patients after different types of allogeneic hematopoietic stem cell transplantation].[供体淋巴细胞输注在不同类型异基因造血干细胞移植患者中的疗效]
Ter Arkh. 2013;85(7):26-33.
3
Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.异基因和自体移植治疗血液系统疾病、实体瘤和免疫性疾病:2009 年欧洲的现状。
Bone Marrow Transplant. 2010 Feb;45(2):219-34. doi: 10.1038/bmt.2009.141. Epub 2009 Jul 6.
4
Haematopoietic stem cell transplantation in Hong Kong.香港的造血干细胞移植
Hong Kong Med J. 2009 Jun;15(3 Suppl 3):17-21.
5
Haematopoietic transplants combining a single unrelated cord blood unit and mobilized haematopoietic stem cells from an adult HLA-mismatched third party donor. Comparable results to transplants from HLA-identical related donors in adults with acute leukaemia and myelodysplastic syndromes.采用单份非亲缘脐带血单位联合成年 HLA 不合第三方供者动员造血干细胞进行造血移植。在急性白血病和骨髓增生异常综合征的成年患者中,与 HLA 相合亲缘供者移植相比具有相当的结果。
Best Pract Res Clin Haematol. 2010 Jun;23(2):259-74. doi: 10.1016/j.beha.2010.05.002.
6
Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.异基因干细胞移植治疗成人骨髓增生异常综合征:移植前疾病负担的重要性。
Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.
7
Haematopoietic stem cell transplantation trends in children over the last three decades: a survey by the paediatric diseases working party of the European Group for Blood and Marrow Transplantation.过去三十年儿童造血干细胞移植趋势:欧洲血液与骨髓移植组儿科疾病工作组的一项调查
Bone Marrow Transplant. 2007 Jan;39(2):89-99. doi: 10.1038/sj.bmt.1705550.
8
Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant.第二次异基因造血干细胞移植作为首次移植后复发白血病的治疗方法。
Bone Marrow Transplant. 2000 Jan;25(1):41-5. doi: 10.1038/sj.bmt.1702101.
9
Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.儿童急性淋巴细胞白血病首次复发后的治疗:治愈策略
Haematologica. 2000 Nov;85(11 Suppl):47-53.
10
Improvement over the years of long-term survival in high-risk lymphoma patients treated with hematopoietic stem cell transplantation as consolidation or salvage therapy.多年来,接受造血干细胞移植作为巩固或挽救治疗的高危淋巴瘤患者的长期生存率有所提高。
Transplant Proc. 2013;45(10):3665-7. doi: 10.1016/j.transproceed.2013.11.007.

引用本文的文献

1
Trends in Outcome of Hematopoietic Stem Cell Transplantation: 5000 Transplantations and 30 Years of Single-Center Experience.造血干细胞移植的结局趋势:5000例移植及30年单中心经验
Cancers (Basel). 2023 Sep 28;15(19):4758. doi: 10.3390/cancers15194758.
2
Resistance of bone marrow stroma to genotoxic preconditioning is determined by p53.骨髓基质对遗传毒性预处理的抗性由 p53 决定。
Cell Death Dis. 2021 May 26;12(6):545. doi: 10.1038/s41419-021-03824-3.
3
Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
阿加糖酶α-紫外线 A 病原体灭活血小板保存长达 7 天的临床影响。
Transfusion. 2019 Nov;59(11):3350-3361. doi: 10.1111/trf.15511. Epub 2019 Oct 1.
4
Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study.慢性髓性白血病的异基因移植及酪氨酸激酶抑制剂对生存的影响:一项准实验研究。
Turk J Haematol. 2017 Mar 1;34(1):16-26. doi: 10.4274/tjh.2015.0346. Epub 2016 Apr 18.
5
Efficiency of allogeneic hematopoietic SCT from HLA fully-matched non-sibling relatives: a new prospect of exploiting extended family search.来自 HLA 完全匹配的非同胞亲属的异基因造血干细胞移植的效率:拓展家族搜索的新前景。
Bone Marrow Transplant. 2015 Apr;50(4):545-52. doi: 10.1038/bmt.2014.307. Epub 2015 Jan 26.